Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

Related Keywords

United States ,Spain ,Barcelona ,Comunidad Autonoma De Cataluna ,Switzerland ,America ,Kevin Garey ,Eugenie Basseres ,Davidp Luci ,Company Ph ,Society Or Healthcare Epidemiology Of America ,Global European Society Of Clinical Microbiology ,Trial Oversight Committee ,Data Monitoring Committee ,Exchange Commission On Form ,Infectious Diseases Society Of America ,European Society Of Clinical Microbiology ,Research Scientist ,Acurx Pharmaceuticals ,Nasdaq ,Acurx Pharmaceuticals Inc ,Company Scientific Advisory Board ,University Of Houston College Pharmacy ,Drug Administration ,Exchange Commission ,Prnewswire Acurx Pharmaceuticals Inc ,European Society ,Clinical Microbiology ,Infectious Diseases ,Houston College ,Principal Investigator ,Acurx Scientific Advisory Board ,Double Blind Study ,Ibezapolstat Compared ,Executive Committee ,Ibezapolstat Phase ,Scientific Advisory Board ,Clinical Cure ,Modified Intent ,Treat Population ,Per Protocol Population ,Prescribing Information ,Independent Data Monitoring Committee ,Gram Positive Selective Spectrum ,Qualified Infectious Disease Product ,Generating New Antibiotic Incentives Now ,Clinical Practice Guidelines ,Infectious Diseases Society ,Healthcare Epidemiology ,New England Journal ,Bile Acid ,Private Securities Litigation Reform Act ,Nc ,